Table 1 Characteristics of shortages in the Netherlands 2012–2015, n (%)
Characteristics | All shortages n = 1844 (%) | Sample of shortages n = 324 (%) | p-value of Chi-square test | |
|---|---|---|---|---|
Year shortage started | Â | Â | 0.207 | |
2012 | 387 (21.0) | 58 (18.2) | Â | |
2013 | 439 (23.8) | 77 (24.1) | Â | |
2014 | 470 (25.5) | 77 (24.1) | Â | |
2015 | 548 (29.7) | 112 (35.1) | Â | |
Route of administration | Â | Â | 0.322 | |
Oral | 1046 (56.7) | 168 (52.7) | Â | |
Parenteral | 554 (30.0) | 104 (32.6) | Â | |
Nasal/inhalation | 42 (2.3) | 8 (2.5) | Â | |
Cutaneous | 77 (4.2) | 13 (4.1) | Â | |
Rectal | 25 (1.4) | 8 (2.5) | Â | |
Ocular | 65 (3.5) | 16 (5.0) | Â | |
Other | 35 (1.9) | 7 (2.2) | Â | |
ATC class | Â | Â | 0.325 | |
A | Alimentary tract and metabolism | 168 (9.1) | 27 (8.5) | Â |
B | Blood and blood forming organs | 91 (4.9) | 17 (5.3) | Â |
C | Cardiovascular system | 240 (13.0) | 38 (11.9) | Â |
D | Dermatologicals | 83 (4.5) | 15 (4.7) | Â |
G | Genito-urinary system and sex hormones | 77 (4.2) | 13 (4.1) | Â |
H | Systemic hormonal preparations, excl. sex hormones and insulins | 84 (4.6) | 11 (3.4) | Â |
J | Antiinfectives for systemic use | 311 (16.9) | 59 (18.5) | Â |
L | Antineoplastic and immunomodulating agents | 148 (8.0) | 26 (8.2) | Â |
M | Musculo-skeletal system | 85 (4.6) | 15 (4.7) | Â |
N | Nervous system | 333 (18.1) | 56 (17.6) | Â |
P | Antiparasitic products, insecticides and repellents | 4 (0.2) | 3 (0.9) | Â |
R | Respiratory system | 88 (4.8) | 12 (3.8) | Â |
S | Sensory organs | 78 (4.2) | 17 (5.3) | Â |
V | Various | 54 (2.9) | 15 (4.7) | Â |
Originator or generic product | Â | Â | 0.738 | |
Originator | 1011 (54.8) | 176 (54.3) | Â | |
Generic product | 833 (45.2) | 148 (45.7) | Â | |